Patterson-UTI Energy, Inc. logo PTEN - Patterson-UTI Energy, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 27
HOLD 18
SELL 7
STRONG
SELL 0
| PRICE TARGET: $12.14 DETAILS
HIGH: $15.00
LOW: $10.00
MEDIAN: $12.00
CONSENSUS: $12.14
UPSIDE: 24.44%

Stock News

Patterson-UTI Energy Inc: Consider Holding On To This Oil Drilling Company As The Strait Of Hormuz Reopens

Patterson-UTI Energy Inc: Consider Holding On To This Oil Drilling Company As The Strait Of Hormuz Reopens

Patterson-UTI Energy, Inc. (PTEN) is rated a hold due to short-term oil price volatility and long-term demand uncertainty. PTEN's Q1 2026 revenue declined 12.75% YoY, with negative net income in six of the last seven quarters. DCF analysis implies a $27.08 intrinsic value per share, but near-term oil price declines suggest PTEN will likely remain below $11 in the next year.

Jul 01, 2026 02:12 PM • seekingalpha.com
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC), as detected by a US Food and Drug Administration (FDA)-authorized test.1 The approval by the US FDA was bas.

Jun 12, 2026 02:44 PM • businesswire.com

Price Targets